At her annual physical examination, an asymptomatic 68-year-old woman has lymphocytosis (32 × 10^9/L) with a normal hemoglobin level and platelet count. On examination, she has 1-cm lymphadenopathy in the cervical region and no palpable liver or spleen enlargement. A peripheral blood smear shows identically appearing mature lymphocytes with smudge cells. Flow cytometry of the peripheral blood lymphocytes shows a monoclonal B population with dim expression of λ light chain and CD20 that is positive for expression of CD5, CD19, and CD23. Which of the following is the best next step in her management?
Rationale:
Active monitoring for disease progression and complications.
This patient displays characteristics of chronic lymphocytic leukemia (CLL) without symptoms requiring immediate treatment. The lymphocytosis and lymphadenopathy suggest a stable condition, making observation the most prudent approach rather than initiating aggressive therapy.
A: Combination chemoimmunotherapy involves more aggressive treatment, which is unnecessary for this asymptomatic patient with stable CLL and no immediate complications.
B: Chlorambucil therapy is typically reserved for symptomatic patients; initiating it in an asymptomatic individual could expose her to unnecessary side effects and complications.
C: Allogeneic peripheral blood stem cell transplant is an invasive option meant for high-risk or symptomatic cases, which does not apply to this patient’s current asymptomatic status.
A 48-year-old man presents to the emergency department with a 6-week history of progressively worsening abdominal pain and night sweats. Physical examination findings were significant for palpable bilateral 2-cm axillary lymph nodes and diffuse abdominal tenderness with no rebound or guarding. Computed tomography of the abdomen and pelvis showed retroperitoneal and mesenteric lymphadenopathy. Excisional biopsy of an axillary node was positive for diffuse, large B-cell lymphoma. Positron emission tomography showed fluorodeoxyglucose-avidity in the axillary, mesenteric, and retroperitoneal lymph nodes. Results of the bone marrow examination were normal. Which of the following is the best next step?
Rationale:
Combination therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the best next step.
R-CHOP is specifically recommended for treating diffuse large B-cell lymphoma, which this patient has, as it effectively targets the aggressive nature of the disease, improving outcomes and survival rates. The patient's presentation aligns with the need for immediate intervention.
B: Observation provides no therapeutic benefit in this case, as the patient's aggressive lymphoma requires prompt treatment rather than a wait-and-see approach that could worsen outcomes.
C: Combination therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) lacks rituximab, which is crucial for enhancing treatment efficacy against diffuse large B-cell lymphoma, making it less optimal.
D: Autologous stem cell transplant is typically considered after initial chemotherapy for relapsed or refractory disease; this patient requires immediate treatment rather than proceeding to transplant at this stage.
The parent of a child diagnosed with Wilms tumor asks about the treatment plan. What should the nurse explain?
Rationale:
The child will have surgery to remove the tumor and kidney, followed by chemotherapy. This combination is the standard approach for Wilms tumor, aiming to ensure complete tumor removal while addressing potential metastasis through chemotherapy.
A: The child will have chemotherapy followed by radiation. This sequence does not prioritize tumor removal, which is critical for effective treatment of Wilms tumor.
B: The child will need surgery to remove the tumor. This option lacks the necessary follow-up chemotherapy, which is essential for preventing recurrence and managing any remaining cancer cells.
D: The child will need radiation first, then surgery. Starting with radiation is not standard practice, as surgical removal is crucial in managing Wilms tumor effectively.
The BEST treatment option for factor VIII hemophiliacs with high titer inhibitor is
Rationale:
D: recombinant factor VIIa is the optimal treatment for factor VIII hemophiliacs with high titer inhibitors as it bypasses the inhibited factor and effectively promotes hemostasis in these patients.
A: continuous infusion of factor VIII does not address the presence of inhibitors, making it ineffective in achieving adequate hemostatic control for patients with high titer inhibitors.
B: immune modulators can be used to help reduce inhibitor levels but are not direct treatments for bleeding episodes, thus lacking immediate hemostatic efficacy in these cases.
C: activated prothrombin complex concentrate is beneficial for treating bleeding, but it is not as effective as recombinant factor VIIa in hemophiliacs with high titer inhibitors targeting specific needs.
A healthy 5-mo-old boy appears pale. Examination is unremarkable. Lab findings include: Hb 8.1 g/dl; WBC 4,800/mm3; platelets 144,000/mm3; MCV, 111 fl; blood film showed hypersegmented neutrophils; serum B12, 65 pg/mL (low). The infant is vigorously breast fed. Of the following, the NEXT step of the management is
Rationale:
Checking the serum B12 of the mother is the next step in management. This infant's symptoms suggest vitamin B12 deficiency, likely due to inadequate maternal intake, which warrants further investigation of maternal B12 levels.
A: performing Schilling test This test assesses vitamin B12 absorption but is not appropriate in this case, as the immediate concern is determining maternal B12 status for the infant's deficiency.
C: parenteral administration of vitamin B12 While this could address the infant’s deficiency, it's premature without first evaluating the mother's serum B12 levels to understand the underlying cause.
D: administration of both folic acid and vitamin B12 Providing both vitamins simultaneously may not be necessary; clarifying maternal B12 levels is crucial before deciding on treatment for the infant.
Which of the following conditions affects partial thromboplastin time?
Rationale:
Disseminated intravascular coagulation affects partial thromboplastin time. This condition results in widespread clotting and subsequent consumption of clotting factors, leading to prolonged partial thromboplastin time as the body attempts to manage coagulation and fibrinolysis simultaneously.
B: Thrombocytopenia results in reduced platelet count, primarily affecting bleeding time rather than partial thromboplastin time, as it does not directly impact the clotting factors involved in this test.
C: Thrombasthenia is a disorder affecting platelet function, which influences bleeding and aggregation but does not directly alter partial thromboplastin time measurements associated with the intrinsic pathway of coagulation.
D: Hemangioma is a benign vascular tumor that does not influence coagulation pathways or partial thromboplastin time, as it does not pertain to blood clotting factors or their activity.
Blood transfusion therapy in a child with sickle cell anemia is indicated in all the following conditions EXCEPT
Rationale:
Blood transfusion therapy in a child with sickle cell anemia is indicated in chronic intolerable pain syndrome. This condition does not typically require transfusion as pain management can often be achieved with other therapies.
A: acute chest syndrome Transfusion is crucial in acute chest syndrome to improve oxygenation and reduce the risk of severe complications associated with respiratory distress.
B: stroke Blood transfusion is vital in stroke prevention in sickle cell anemia to decrease the risk of further ischemic events and manage hemoglobin levels effectively.
D: avascular necrosis of the hip joint Transfusion may not be necessary for avascular necrosis, as management usually focuses on pain relief and orthopedic interventions rather than addressing the underlying sickle cell pathology directly.
The definitive diagnostic test for the condition described in Question 19 is
Rationale:
The definitive diagnostic test for the condition described in Question 19 is an osmotic fragility test. This test specifically assesses the stability of red blood cells under varying osmotic conditions, which is crucial for diagnosing certain hemolytic anemias linked to membrane defects.
A: an enzyme assay This test evaluates enzyme levels but does not directly assess red blood cell integrity, making it unsuitable for diagnosing the specific condition in question.
B: a stool Hemoccult test This screening method detects hidden blood in stool samples, primarily for gastrointestinal issues, lacking relevance to the assessment of red blood cell fragility.
C: chest radiography This imaging technique focuses on abnormalities in the chest cavity and has no bearing on diagnosing conditions related to red blood cells or their fragility.
A 13-month-old girl presented with progressive pallor for the last 3 months. The mother noticed that she started to eat a non-nutritive and dirty substance. She is on breast feeding till this age. On examination, she is pale, apathetic looking, no LAP, no organomegaly, and no skin bleeds. Of the following, the MOST likely diagnosis is:
Rationale:
Iron deficiency anemia is the most likely diagnosis. The girl's progressive pallor, combined with her non-nutritive eating behavior (pica), suggests iron deficiency, which is common in breastfed infants lacking iron-rich foods.
B: Folic acid deficiency typically presents with macrocytic anemia and is less likely in this context, as the symptoms do not align with folate deficiency.
C: Vitamin B12 deficiency usually causes neurological symptoms and macrocytic anemia, which are not evident in this case, making it an unlikely diagnosis.
D: Vitamin E deficiency primarily leads to neurological issues and hemolytic anemia, neither of which are present in this child's clinical picture, ruling it out as a diagnosis.
What are the clinical manifestations of non-Hodgkin lymphoma?
Rationale:
They depend on the anatomical site and extent of involvement. Non-Hodgkin lymphoma presents with a variety of symptoms that vary significantly based on where the lymphoma develops and how widespread it is within the body, making the clinical manifestations highly diverse.
A: They are basically the same as those in Hodgkin disease. Non-Hodgkin lymphoma has distinct features and symptoms that differentiate it from Hodgkin disease, highlighting the unique nature of each type.
C: They typically affect the abdomen in very young children. While abdominal involvement can occur, non-Hodgkin lymphoma manifests in various sites, not limited to young children or the abdominal region.
D: They mainly cause changes in the lower extremities. Non-Hodgkin lymphoma can affect multiple areas of the body, not specifically causing changes limited to the lower extremities.
Matching: For each of the following disorders, select the appropriate platelet presentation - Kasabach-Merritt syndrome
Rationale:
Platelets decreased in number. Kasabach-Merritt syndrome is characterized by a hemangioma causing thrombocytopenia, where the formation of a vascular tumor leads to the consumption of platelets, resulting in a reduced platelet count.
B: Platelet count normal. A normal platelet count contradicts the fundamental pathology of Kasabach-Merritt syndrome, where significant platelet consumption occurs due to the presence of a vascular tumor.
C: Platelets increased. An increased platelet count does not align with the syndrome's mechanism, which is associated with thrombocytopenia rather than an overproduction of platelets in response to the vascular tumor.
All the following are true regarding factor XIII EXCEPT
Rationale:
Factor XIII deficiency does not prolong PT, PTT, or thrombin time (TT), making option B the exception among the statements provided.
Factor XIII is primarily involved in cross-linking fibrin, which does not affect PT, PTT, or TT, tests for other coagulation factors. These tests measure different pathways, hence a deficiency in factor XIII would not lead to prolonged results in them.
A: the half-life is 5-7 days. Factor XIII has a notably long half-life, which is accurately represented by this statement, confirming its stability in circulation.
C: clot solubility test with 5 m urea is a screening test for factor XIII deficiency. This test specifically assesses the stability of fibrin clots, directly correlating to factor XIII function, making it a valid screening method.
D: factor assay is a specific test to detect its level. A factor assay is indeed a precise measure of factor XIII levels in the blood, confirming the functionality and quantity of this factor.
When caring for a child with lymphoma, the nurse should be aware that:
Rationale:
Aggressive chemotherapy with central nervous system prophylaxis can improve prognosis. This approach enhances the effectiveness of treatment and minimizes the risk of disease spread to the central nervous system, which is crucial in pediatric lymphoma management.
A: The same staging system is used for lymphoma and Hodgkin disease. Each condition has distinct staging criteria tailored to their unique biological characteristics, making a unified system inappropriate.
C: All children with lymphoma require a bone marrow transplant. Many cases of lymphoma can be effectively treated with chemotherapy alone, making transplants unnecessary for all patients.
D: The prognosis is very poor despite high-dose chemotherapy. While challenges exist, many children respond well to high-dose chemotherapy, leading to favorable outcomes and improved survival rates.
The bleeding time is a test for
Rationale:
The bleeding time is a test for platelet function. This test evaluates the ability of platelets to adhere to blood vessel walls and aggregate, which is crucial for effective hemostasis during injury.
A: fibrinogen Measures the presence of fibrinogen, a protein essential for clot formation, but does not assess the functionality of platelets in the bleeding process.
B: antithrombin III activity This test evaluates the inhibitory function on clotting factors but does not relate to the direct action of platelets in the bleeding response.
D: factor VIII coagulant activity This option tests a specific clotting factor involved in hemophilia but is not indicative of the overall function and effectiveness of platelets.
A child receiving extensive radiation for Hodgkin disease may experience which side effect that requires nursing intervention?
Rationale:
C: Provide adequate rest due to malaise and low energy. Extensive radiation can lead to significant fatigue and malaise, necessitating nursing interventions to ensure the child receives adequate rest for recovery and overall well-being.
A: Administer pain medication prior to radiation therapy. While pain management is important, it does not specifically address the fatigue or energy depletion commonly experienced during extensive radiation treatment.
B: Assess for neuropathy. Neuropathy is not a typical side effect associated with radiation therapy for Hodgkin disease, making this assessment less relevant in the context of expected side effects.
D: Encourage a low-protein diet. Radiation therapy generally necessitates a balanced diet, and a low-protein diet could hinder recovery and overall health, contradicting the nutritional needs of the child during treatment.
Which analgesic is most effective for a child with sickle cell pain crisis?
Rationale:
Morphine is the most effective analgesic for a child with a sickle cell pain crisis. This opioid is highly effective in managing severe pain associated with sickle cell crises, offering significant relief by binding to opioid receptors in the brain, thus altering pain perception and improving patient comfort during acute episodes.
A: Demerol provides short-term relief but is less effective than morphine for severe pain management in sickle cell crises. Its potential side effects also make it a less favorable choice.
B: Aspirin may help with mild pain relief but does not address the severe pain typical of sickle cell crises. It also carries risks of gastrointestinal complications in children.
D: Excedrin, primarily a combination of acetaminophen and aspirin, lacks the potency needed for severe pain associated with sickle cell crises, making it unsuitable for effective management in this context.
Matching: For each of the following disorders, select the appropriate platelet presentation - ITP
Rationale:
Platelets decreased in number.
In Immune Thrombocytopenic Purpura (ITP), platelet destruction occurs due to an autoimmune response, resulting in significantly reduced platelet counts. This reduction leads to increased risk of bleeding, making it crucial to recognize the association between ITP and low platelet levels for effective management and treatment strategies.
B: Platelet count normal. Normal platelet levels contradict the fundamental pathology of ITP, where the primary characteristic is a significant decrease in platelet count due to immune-mediated destruction.
C: Platelets increased. Elevated platelet counts do not align with ITP, as the disorder specifically involves a decrease in platelets, leading to a heightened risk of bleeding complications rather than increased production.
All of the following are true about the reptilase time EXCEPT
Rationale:
Reptilase time is not always prolonged when the thrombin time is prolonged. While thrombin time may indicate various deficiencies, reptilase can remain normal despite an extended thrombin time due to its unique sensitivity profile.
A: it is not sensitive to heparin. Reptilase time remains unaffected by heparin, allowing for accurate assessment of fibrinogen function in anticoagulated patients.
B: it is prolonged by reduced fibrinogen. A decrease in fibrinogen levels directly impacts clot formation, leading to a prolonged reptilase time, which reflects the underlying fibrinogen deficiency.
C: it is prolonged by dysfunctional fibrinogen. Dysfunctional fibrinogen will hinder proper clot formation, thus leading to an extended reptilase time, indicating the impairment in fibrinogen's structural integrity.
Which of the following results correctly fits the expected transfusion outcome?
Rationale:
Cryoprecipitate; rise of fibrinogen by 50-100 mg/dl. This option accurately reflects the expected increase in fibrinogen levels after administering cryoprecipitate, making it a crucial component in managing coagulopathy effectively.
A: packed red blood cell; rise of Hb by 5-7 gm/dl. This statement overestimates the typical hemoglobin increase, which usually occurs in a range lower than specified after transfusion.
B: platelets concentrate; rise of platelets by 80.000-100.000/ml. This value is unrealistic as platelet transfusions generally yield a smaller increase, not aligning with standard clinical expectations for platelet increments.
D: recombinant factor VIII; rise of factor VIII by 0.5%/unit/kg. This increment underrepresents the expected elevation, as factor VIII administration typically results in a much larger percentage increase per unit administered.
Matching: Anemia - Iron deficiency
Rationale:
Anemia is classified as microcytic when it is due to iron deficiency. This type of anemia features smaller than normal red blood cells, which results from inadequate iron for hemoglobin synthesis.
B: Normocytic Red blood cells retain normal size in normocytic anemia, typically indicating conditions like chronic disease or acute blood loss, which do not relate to iron deficiency.
C: Macrocytic Anemia characterized as macrocytic involves larger than average red blood cells, often stemming from deficiencies like vitamin B12 or folate, distinct from iron deficiency causes.
Which of the following can lead to a possible diagnosis of human immunodeficiency virus (HIV) in a child? (Select one that does not apply.)
Rationale:
D: Irregular heartbeat. Irregular heartbeat does not typically indicate HIV in children, as it is not a common symptom associated with the virus. Instead, it usually relates to other cardiovascular or respiratory issues unrelated to HIV infection.
A: Repeated respiratory infections signify a compromised immune system, which can be a symptom of HIV, as the virus impairs the body’s ability to fend off infections.
B: Intermittent diarrhea often indicates gastrointestinal issues, which can arise from HIV-related complications, as the virus can affect the immune response and lead to persistent infections.
C: Poor weight gain reflects malnutrition or chronic illness, often seen in children with HIV, as the virus can hinder nutrient absorption and overall health, impacting growth and development.
Matching: Regional lymphadenopathy - Yersinia
Rationale:
Regional lymphadenopathy is most commonly associated with mesenteric lymph nodes in Yersinia infections. This bacterium typically leads to abdominal symptoms, prompting enlargement of lymph nodes in the mesenteric area due to the immune response.
A: Cervical Lymphadenopathy in Yersinia is less common, as this infection primarily affects the gastrointestinal tract rather than the head and neck area where cervical nodes are located.
B: Occipital Lymphadenopathy does not typically occur with Yersinia infections, as the pathogen is more associated with abdominal symptoms and the mesenteric lymphatic region rather than the occipital area.
D: Mediastinal Lymphadenopathy is not characteristic of Yersinia infections, which primarily involve the gastrointestinal system and lead to mesenteric lymph node enlargement rather than those located in the mediastinal region.
Anemia and reticulocytopenia that occur in the 2nd half of infancy period is LEAST likely due to
Rationale:
Anemia and reticulocytopenia in the 2nd half of infancy is least likely due to congenital hypoplastic anemia (Diamond-Blackfan anemia).
Congenital hypoplastic anemia typically presents earlier in life, characterized by inadequate erythropoiesis. This condition leads to significant anemia and reticulocytopenia in infancy, making it an unlikely cause during the later stages of this developmental period.
B: transient erythroblastopenia of childhood This condition commonly arises in young children, causing reticulocytopenia and is more prevalent in the 2nd half of infancy.
C: a protracted, prolonged course of the anemia of hemolytic disease of the newborn This anemia persists beyond the immediate newborn phase and can manifest during the latter part of infancy.
D: aplastic crises complicating various types of chronic hemolytic anemias Aplastic crises can occur in chronic hemolytic anemias and may lead to reticulocytopenia during the latter half of infancy.
The main reason behind gamma irradiation of the blood products is to prevent
Rationale:
Gamma irradiation of blood products is performed to prevent graft-versus-host disease (GVHD). This technique effectively inactivates donor immune cells that can attack the recipient's tissues, thereby ensuring patient safety and reducing complications post-transfusion.
A: transfusion-related bacterial infections Bacterial infections are typically managed through proper screening and storage, not gamma irradiation, which specifically targets immune cell activity rather than pathogens in blood products.
B: transfusion-related viral infections Gamma irradiation does not specifically address viral infections, as viral safety is primarily ensured through donor screening and nucleic acid testing rather than irradiation techniques.
D: allergic reactions Allergic reactions are primarily caused by recipient sensitivities to blood components, which cannot be mitigated through gamma irradiation, making other preventive measures necessary to address this issue.
A 45-year-old man presents with deep vein thrombosis of the right femoral vein. Three months ago, he received a diagnosis of systemic lupus erythematosus (SLE). In addition to confirming SLE, laboratory testing also documented the presence of a lupus anticoagulant (LAC). There is no family history of venous thrombosis. Current medications include hydroxychloroquine. Laboratory testing shows normal results for a complete blood cell count and for tests of liver and kidney function. Special coagulation testing confirms the persistence of an LAC. What is the most reasonable duration of warfarin anticoagulation for this patient?
Rationale:
Long-term anticoagulation is warranted for this patient due to the presence of lupus anticoagulant, which significantly increases the risk of recurrent thromboembolic events in individuals with systemic lupus erythematosus (SLE).
A: 3 months. This duration is insufficient, as the persistent presence of lupus anticoagulant indicates a heightened risk for future thrombotic events beyond three months.
B: 1 year. While this may seem reasonable, the continued presence of lupus anticoagulant suggests that one year may not fully mitigate the risk of recurrence in this patient.
C: 6 months. Six months does not account for the ongoing thrombotic risk associated with lupus anticoagulant; long-term anticoagulation is necessary to provide adequate protection against future events.
A 3.2-kg, 40-week's-gestational age male is born by spontaneous vaginal delivery to a 20-year-old white female. Past maternal medical problems reveal a history of easy bruising that required splenectomy at 18 years of age. Current coagulation studies of the mother include a prothrombin time of 12 seconds, a partial thromboplastin time of 25 seconds, fibrinogen of 300 mg/dL, and a platelet count of 175,000. At 3 hours of age, the infant is noted to have multiple petechiae and a platelet count of 15,000. The most likely diagnosis is
Rationale:
C: maternal idiopathic thrombocytopenic purpura. The mother’s history of easy bruising and splenectomy indicates a potential underlying platelet disorder, leading to the infant's thrombocytopenia due to maternal antibodies affecting the newborn.
A: neonatal alloimmune thrombocytopenia. This condition arises from maternal antibodies targeting fetal platelets; however, the mother’s history suggests her own thrombocytopenia likely affects the infant’s platelet count.
B: congenital von Willebrand disease. This disorder involves defective platelet function and typically presents with bleeding issues, but the infant's severe thrombocytopenia directly correlates with maternal ITP rather than a congenital condition.
D: congenital leukemia. While leukemia can cause thrombocytopenia, the sudden onset in a newborn and the mother’s medical history point more accurately to maternal idiopathic thrombocytopenic purpura as the underlying cause.
The criteria for successful bone marrow transplantation in thalassemic patients include all the following EXCEPT
Rationale:
Successful bone marrow transplantation in thalassemic patients does not necessitate the absence of bone deformities, as these can be managed post-transplant and do not preclude eligibility for the procedure.
A: age younger than 15-year-old Patients typically achieve better outcomes when younger than 15, as their bodies are more resilient and capable of recovering from the transplant process.
B: no hepatomegaly Hepatomegaly indicates liver enlargement, often a complication of thalassemia, and its presence can complicate the procedure but does not automatically disqualify patients from transplantation.
D: no iron overload Iron overload is a common issue in thalassemia due to repeated blood transfusions, yet it can be treated and managed, thus not ruling out transplant eligibility.
Ten years later, the patient described in Questions 3 and 4 experiences recurrent hemarthroses that become refractory to standard doses of factor VIII. The most likely cause of this is
Rationale:
B: The presence of factor VIII antibodies suggests an acquired inhibitor, which can lead to recurrence of hemarthroses despite standard factor VIII treatment. This immune response can develop over time, diminishing treatment efficacy.
A: Worsening hemophilia indicates a gradual decline in factor levels, but recurrent hemarthroses refractory to treatment specifically points to an immune-mediated response rather than a simple worsening of the condition.
C: Development of AIDS may contribute to overall health decline, yet it does not directly cause refractory hemarthroses related to factor VIII treatment, making this option less relevant in this context.
D: Development of hepatitis affects liver function and can impact clotting factors, but it does not specifically explain the emergence of refractory hemarthroses associated with factor VIII therapy.
Of the following, the LEAST likely feature of Bernard-Soulier syndrome is
Rationale:
The least likely feature of Bernard-Soulier syndrome is severe thrombocytopenia. This condition is characterized by a mild to moderate reduction in platelet count, predominantly presenting with larger platelets, not a severe deficiency.
A: autosomal recessive inheritance This genetic pattern is associated with Bernard-Soulier syndrome, indicating that both parents contribute to the inheritance, making it a relevant feature of the disease.
C: giant Platelets Bernard-Soulier syndrome is characterized by the presence of abnormally large platelets, reflecting the underlying defect in platelet formation, thus marking it as a definitive feature.
D: abnormal ristocetin test The syndrome is characterized by a specific abnormality in the ristocetin test, which reveals the functional defect in platelet aggregation, making this a typical finding.
The best diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH) is
Rationale:
D: Flow cytometry is the best diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH) as it accurately identifies defective glycosylphosphatidylinositol (GPI)-anchored proteins on blood cells, confirming the diagnosis effectively and rapidly.
A: Acidified serum hemolysis (HAM) test lacks specificity and sensitivity for PNH, often leading to false positives or negatives, making it less reliable for definitive diagnosis.
B: Sucrose lysis test primarily detects complement-mediated hemolysis, which does not specifically diagnose PNH, as it doesn't evaluate the GPI-anchor defect necessary for confirmation.
C: Complement assay assesses hemolytic activity but does not directly identify the GPI-anchored protein deficiency characteristic of PNH, rendering it insufficient for accurate diagnosis.
At her annual physical examination, an asymptomatic 68-year-old woman has lymphocytosis (32 × 10^9/L) with a normal hemoglobin level and platelet count. On examination, she has 1-cm lymphadenopathy in the cervical region and no palpable liver or spleen enlargement. A peripheral blood smear shows identically appearing mature lymphocytes with smudge cells. Flow cytometry of the peripheral blood lymphocytes shows a monoclonal B population with dim expression of λ light chain and CD20 that is positive for expression of CD5, CD19, and CD23. Which of the following is the best next step in her management?
Rationale:
Active monitoring for disease progression and complications is the best next step in her management.
This patient exhibits characteristics consistent with chronic lymphocytic leukemia (CLL), which often requires observation initially, especially when asymptomatic and with stable disease indicators. Active monitoring allows for timely intervention if symptoms or disease progression occurs.
A: Combination chemoimmunotherapy involves immediate treatment, which is not warranted given her asymptomatic state and stable blood counts.
B: Chlorambucil therapy represents a treatment option for symptomatic CLL, but she currently shows no indications for active intervention.
C: Allogeneic peripheral blood stem cell transplant is reserved for high-risk cases and is inappropriate for this patient, who does not exhibit aggressive disease features.
A 48-year-old man presents to the emergency department with a 6-week history of progressively worsening abdominal pain and night sweats. Physical examination findings were significant for palpable bilateral 2-cm axillary lymph nodes and diffuse abdominal tenderness with no rebound or guarding. Computed tomography of the abdomen and pelvis showed retroperitoneal and mesenteric lymphadenopathy. Excisional biopsy of an axillary node was positive for diffuse, large B-cell lymphoma. Positron emission tomography showed fluorodeoxyglucose-avidity in the axillary, mesenteric, and retroperitoneal lymph nodes. Results of the bone marrow examination were normal. Which of the following is the best next step?
Rationale:
Combination therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the best next step for this patient diagnosed with diffuse, large B-cell lymphoma, as it effectively targets aggressive lymphoma and improves outcomes.
B: Observation lacks active treatment and is unsuitable for aggressive lymphoma, as it allows disease progression without addressing the patient's significant symptoms and lymphadenopathy.
C: Combination therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) does not include rituximab, which is crucial for enhancing treatment efficacy in large B-cell lymphoma cases.
D: Autologous stem cell transplant is not the initial step in management for this patient; it is typically considered after first-line therapy or in relapsed cases of lymphoma.
The parent of a child diagnosed with Wilms tumor asks about the treatment plan. What should the nurse explain?
Rationale:
The child will have surgery to remove the tumor and kidney, followed by chemotherapy. This approach is standard for Wilms tumor, as it aims to eliminate the cancerous growth effectively while preserving the child's overall health through subsequent chemotherapy.
A: The child will have chemotherapy followed by radiation. This sequence is not typical; initial surgery is crucial for effective tumor removal before considering chemotherapy.
B: The child will need surgery to remove the tumor. While surgery is essential, it must be followed by chemotherapy to address any remaining cancer cells and prevent recurrence.
D: The child will need radiation first, then surgery. Starting with radiation contradicts established treatment protocols for Wilms tumor, where surgical intervention is prioritized to excise the tumor promptly.
The BEST treatment option for factor VIII hemophiliacs with high titer inhibitor is
Rationale:
D: recombinant factor VIIa effectively bypasses the factor VIII deficiency and is particularly useful in patients with high-titer inhibitors. It activates the coagulation cascade, promoting hemostasis even in the presence of inhibitors.
A: continuous infusion of factor VIII fails to address the challenge posed by high-titer inhibitors, which neutralize infused factor VIII, rendering this approach ineffective for achieving adequate hemostatic levels.
B: immune modulators typically focus on immune response regulation and may not directly enhance coagulation in patients with severe hemophilia and high-titer inhibitors, making them less suitable for immediate treatment needs.
C: activated prothrombin complex concentrate, while useful in some bleeding scenarios, does not specifically target the unique challenges associated with high-titer inhibitors in factor VIII hemophilia, thus limiting its effectiveness.
A healthy 5-mo-old boy appears pale. Examination is unremarkable. Lab findings include: Hb 8.1 g/dl; WBC 4,800/mm3; platelets 144,000/mm3; MCV, 111 fl; blood film showed hypersegmented neutrophils; serum B12, 65 pg/mL (low). The infant is vigorously breast fed. Of the following, the NEXT step of the management is
Rationale:
Checking the serum B12 of the mother is the next step in management. The infant’s low serum B12 suggests a potential deficiency from maternal sources, particularly given the vigorous breastfeeding. Identifying maternal B12 levels can clarify if the infant's condition stems from inadequate maternal intake or absorption issues, guiding appropriate treatment.
A: Performing Schilling test evaluates B12 absorption but is not immediately pertinent. The infant's symptoms necessitate addressing potential maternal deficiencies before exploring complex absorption issues.
C: Parenteral administration of vitamin B12 bypasses investigation of maternal levels. This intervention might be premature without confirming whether maternal B12 deficiency contributes to the infant’s low serum levels.
D: Administration of both folic acid and vitamin B12 may address broader deficiencies but does not prioritize determining maternal B12 status. This dual approach lacks specificity for the infant's identified deficiency.
Which of the following conditions affects partial thromboplastin time?
Rationale:
Disseminated intravascular coagulation affects partial thromboplastin time. This condition leads to widespread clotting in small blood vessels, depleting clotting factors and prolonging the partial thromboplastin time, indicating impaired coagulation.
B: Thrombocytopenia impacts platelet count but does not directly influence the clotting factors measured by partial thromboplastin time, which assesses the intrinsic pathway of coagulation.
C: Thrombasthenia involves a defect in platelet function that can affect bleeding time but does not typically alter partial thromboplastin time measured in coagulation tests.
D: Hemangioma refers to a benign vascular tumor and does not have a direct effect on the coagulation pathways assessed by partial thromboplastin time.
Blood transfusion therapy in a child with sickle cell anemia is indicated in all the following conditions EXCEPT
Rationale:
Blood transfusion therapy in a child with sickle cell anemia is indicated in chronic intolerable pain syndrome. Chronic pain management typically does not require transfusions, as it focuses on analgesics and supportive care.
A: acute chest syndrome Blood transfusions are crucial in managing acute chest syndrome to improve oxygenation and reduce complications.
B: stroke Transfusions are essential following a stroke to prevent further ischemic damage and ensure proper blood flow to the brain.
D: avascular necrosis of the hip joint While painful, avascular necrosis does not necessitate transfusions; management focuses on orthopedic interventions rather than blood products.
The definitive diagnostic test for the condition described in Question 19 is
Rationale:
D: an osmotic fragility test. This test specifically evaluates red blood cell membrane stability, making it the definitive diagnostic tool for conditions associated with increased fragility, such as hereditary spherocytosis or thalassemia.
A: an enzyme assay. While enzyme assays can identify specific metabolic disorders, they do not assess red blood cell fragility, which is crucial for diagnosing the condition in question.
B: a stool Hemoccult test. This test screens for hidden blood in stool, primarily indicating gastrointestinal bleeding, and does not provide relevant information about red blood cell membrane integrity or fragility.
C: chest radiography. Chest X-rays assess lung conditions and cardiac silhouette but have no relevance to diagnosing issues related to red blood cell stability or osmotic fragility.
A 13-month-old girl presented with progressive pallor for the last 3 months. The mother noticed that she started to eat a non-nutritive and dirty substance. She is on breast feeding till this age. On examination, she is pale, apathetic looking, no LAP, no organomegaly, and no skin bleeds. Of the following, the MOST likely diagnosis is:
Rationale:
A 13-month-old girl is most likely diagnosed with iron deficiency anemia. The presentation of progressive pallor, non-nutritive eating behavior, and a lack of significant clinical findings suggests a nutritional deficiency, particularly iron, commonly seen in young children.
B: folic acid deficiency Presents with megaloblastic anemia and neurological symptoms, which are not observed in this case, as the child exhibits no such clinical signs or symptoms.
C: Bâ‚‚ deficiency Typically causes neurological issues and macrocytic anemia, neither of which align with the pallor and general clinical presentation observed in this 13-month-old girl.
D: vitamin E deficiency Primarily leads to neurological problems and hemolytic anemia, which are absent in this scenario, as evidenced by the lack of organomegaly and skin bleeds.
What are the clinical manifestations of non-Hodgkin lymphoma?
Rationale:
Non-Hodgkin lymphoma's clinical manifestations depend on the anatomical site and extent of involvement. This variability leads to a range of symptoms influenced by the location of the lymphoma in the body.
A: They are basically the same as those in Hodgkin disease. Non-Hodgkin lymphoma and Hodgkin disease exhibit distinct clinical features, making this comparison misleading and oversimplified.
C: They typically affect the abdomen in very young children. While abdominal involvement can occur, non-Hodgkin lymphoma presents diversely across various age groups and anatomical sites, not limited to children.
D: They mainly cause changes in the lower extremities. Symptoms of non-Hodgkin lymphoma are not restricted to the lower extremities; they can manifest in multiple locations throughout the body.
Matching: For each of the following disorders, select the appropriate platelet presentation - Kasabach-Merritt syndrome
Rationale:
Platelets decreased in number. Kasabach-Merritt syndrome is characterized by a significant reduction in platelet count due to the consumption of platelets by a vascular tumor, leading to thrombocytopenia and associated complications.
B: Platelet count normal Normal platelet counts do not align with Kasabach-Merritt syndrome, where the pathological process actively reduces platelets due to their consumption in the tumor's microenvironment.
C: Platelets increased Increased platelet counts are not typical in this syndrome, as the condition specifically involves decreased platelet levels resulting from their consumption rather than production or release from the bone marrow.
All the following are true regarding factor XIII EXCEPT
Rationale:
Factor XIII deficiency does not prolong PT, PTT, or thrombin time, as these tests primarily assess the extrinsic and intrinsic pathways, not the final stages of clot stabilization where factor XIII is involved.
A: the half-life is 5-7 days. This duration accurately reflects the stability of factor XIII in circulation, which is essential for its role in promoting clot integrity.
C: clot solubility test with 5 m urea is a screening test for factor XIII deficiency. This test specifically evaluates clot stability, providing insight into factor XIII function, rather than deficiency.
D: factor assay is a specific test to detect its level. This assay accurately quantifies factor XIII levels, offering a direct measurement relevant to diagnosing deficiencies effectively.
When caring for a child with lymphoma, the nurse should be aware that:
Rationale:
Aggressive chemotherapy with central nervous system prophylaxis can improve prognosis. This approach helps to target cancer cells effectively while preventing metastasis to the central nervous system, which is crucial for enhancing survival rates in pediatric lymphoma patients.
A: The same staging system is used for lymphoma and Hodgkin disease. Distinct staging systems exist for non-Hodgkin lymphoma and Hodgkin disease, reflecting their different biological behaviors and treatment strategies.
C: All children with lymphoma require a bone marrow transplant. Not all pediatric lymphoma cases necessitate a bone marrow transplant; treatment plans vary based on the specific type and stage of the disease.
D: The prognosis is very poor despite high-dose chemotherapy. While prognosis can be challenging, high-dose chemotherapy often leads to significant improvements in outcomes, contradicting the assumption of uniformly poor prognosis.
The bleeding time is a test for
Rationale:
The bleeding time is a test for platelet function. This test assesses how well platelets adhere to blood vessel walls and aggregate, which is essential for effective hemostasis during bleeding episodes.
A: fibrinogen Assessing fibrinogen levels focuses on the clotting process rather than the initial platelet function, which is critical for immediate hemostatic response to vascular injury.
B: antithrombin III activity Antithrombin III primarily regulates coagulation by inhibiting thrombin and factor Xa, thus impacting clot formation rather than the actual platelet aggregation and adherence measured in bleeding time.
D: factor VIII coagulant activity Factor VIII is crucial for the intrinsic pathway of coagulation and affects clotting but does not evaluate the primary platelet function involved in controlling bleeding time.
A child receiving extensive radiation for Hodgkin disease may experience which side effect that requires nursing intervention?
Rationale:
C: Provide adequate rest due to malaise and low energy. Extensive radiation treatment can lead to significant fatigue and malaise, necessitating nursing interventions to ensure the child receives appropriate rest to support recovery and overall well-being.
A: Administer pain medication prior to radiation therapy. While pain management is crucial, it does not specifically address the fatigue and malaise commonly experienced after extensive radiation therapy.
B: Assess for neuropathy. Neuropathy may occur in some cases, but it is not a primary side effect associated with extensive radiation therapy for Hodgkin disease, making this option less relevant.
D: Encourage a low-protein diet. A low-protein diet does not align with the nutritional needs of a child undergoing extensive radiation therapy, where maintaining protein intake is often essential for recovery and healing.
Which analgesic is most effective for a child with sickle cell pain crisis?
Rationale:
Morphine is the most effective analgesic for a child experiencing a sickle cell pain crisis. This opioid is potent and specifically targets severe pain, which is common during such crises, ensuring quick relief and improved comfort for the child.
A: Demerol lacks the efficacy and safety profile of morphine, potentially leading to inadequate pain management and increased side effects in pediatric patients suffering from severe pain.
B: Aspirin is typically used for mild to moderate pain and may not provide sufficient analgesic effect in severe situations like sickle cell pain crises, limiting its usefulness in this context.
D: Excedrin combines acetaminophen and caffeine, making it suitable for headaches rather than severe pain crises, offering minimal relief and not addressing the intensity of pain experienced in sickle cell conditions.
Matching: For each of the following disorders, select the appropriate platelet presentation - ITP
Rationale:
Platelets decreased in number. In the context of Immune Thrombocytopenic Purpura (ITP), the hallmark is a significant reduction in platelet count due to autoimmune destruction, leading to increased bleeding risk and bruising.
B: Platelet count normal. In ITP, patients typically experience a low platelet count, contrasting with the option that suggests stability in platelet levels, which does not align with the disorder's characteristics.
C: Platelets increased. This choice suggests an elevation in platelet count, which contradicts ITP's defining feature of decreased platelets, resulting from the immune system's attack on these cells.
All of the following are true about the reptilase time EXCEPT
Rationale:
Reptilase time is not always prolonged when the thrombin time is prolonged. While thrombin time assesses fibrinogen function, reptilase time specifically evaluates the conversion of fibrinogen to fibrin, which may remain unaffected.
A: it is not sensitive to heparin. Reptilase time measures fibrinogen conversion and is not influenced by heparin, making it useful in certain anticoagulated patients.
B: it is prolonged by reduced fibrinogen. A reduction in fibrinogen levels directly affects coagulation, leading to an increased reptilase time as there is insufficient substrate for fibrin formation.
C: it is prolonged by dysfunctional fibrinogen. Dysfunctional fibrinogen can impede proper fibrin clot formation, causing a prolonged reptilase time due to inadequate functional activity, thereby affecting coagulation efficiency.
Which of the following results correctly fits the expected transfusion outcome?
Rationale:
Cryoprecipitate; rise of fibrinogen by 50-100 mg/dl. This result aligns with the expected effect of cryoprecipitate infusion, which is specifically indicated to increase fibrinogen levels, enhancing coagulation.
A: packed red blood cell; rise of Hb by 5-7 gm/dl. While packed red blood cells can increase hemoglobin, the expected rise is typically less than this range, making it imprecise.
B: platelets concentrate; rise of platelets by 80.000-100.000/ml. The expected increase in platelets after transfusion usually varies more widely, making this estimate less reliable for platelet concentrates.
D: recombinant factor VIII; rise of factor VIII by 0.5%/unit/kg. Factor VIII levels typically increase more significantly with recombinant administration, rendering this estimate too low to accurately reflect the expected outcome.
Matching: Anemia - Iron deficiency
Rationale:
Anemia is classified as microcytic when it results from iron deficiency. This condition leads to the production of smaller-than-normal red blood cells, which is characteristic of microcytic anemia.
B: Normocytic Anemia typically involves red blood cells that are of normal size, often seen in conditions unrelated to iron deficiency, thus failing to represent the microcytic nature of iron deficiency anemia.
C: Macrocytic Anemia features larger-than-normal red blood cells, generally arising from vitamin B12 or folate deficiencies, making it distinctly different from the microcytic classification associated with iron deficiency anemia.
Which of the following can lead to a possible diagnosis of human immunodeficiency virus (HIV) in a child? (Select one that does not apply.)
Rationale:
D: Irregular heartbeat. This symptom does not directly correlate with HIV diagnosis in children. Instead, it may indicate cardiovascular issues unrelated to the immune system's functionality, which HIV primarily affects.
A: Repeated respiratory infections. Frequent respiratory infections often indicate a weakened immune system, which can be a sign of HIV, making this a relevant concern in potential diagnoses.
B: Intermittent diarrhea. Diarrhea can stem from various causes, including infections or malabsorption issues, but in children with compromised immunity, it could suggest HIV-related conditions affecting their overall health.
C: Poor weight gain. This is a significant indicator of malnutrition or chronic illness, and in the context of HIV, it could signify the impact of the virus on a child’s growth and health.
Matching: Regional lymphadenopathy - Yersinia
Rationale:
Regional lymphadenopathy associated with Yersinia is primarily mesenteric. This condition often arises due to gastrointestinal infections, leading to swollen lymph nodes in the mesentery, which is crucial for intestinal immunity.
A: Cervical Lymphadenopathy typically occurs in response to upper respiratory infections, making it less relevant to Yersinia, which mainly affects the gastrointestinal tract and mesenteric lymph nodes.
B: Occipital This type of lymphadenopathy usually relates to infections of the scalp or neck, thus not aligning with Yersinia’s primary association with abdominal lymphatic regions.
D: Mediastinal While mediastinal lymphadenopathy may indicate other infections, it does not pertain to Yersinia, which specifically induces inflammation in the mesenteric lymph nodes of the abdomen.
Anemia and reticulocytopenia that occur in the 2nd half of infancy period is LEAST likely due to
Rationale:
Anemia and reticulocytopenia that occur in the 2nd half of infancy period is least likely due to congenital hypoplastic anemia (Diamond-Blackfan anemia).
This condition typically presents earlier in infancy and is characterized by a marked reduction in red blood cell production due to intrinsic bone marrow failure, contrasting with the other options that manifest later in infancy.
B: Transient erythroblastopenia of childhood This condition arises after six months and usually resolves spontaneously, making it more likely to occur in the latter half of infancy.
C: A protracted, prolonged course of the anemia of hemolytic disease of the newborn This type of anemia can persist beyond the neonatal period, leading to reticulocytopenia during the second half of infancy.
D: Aplastic crises complicating various types of chronic hemolytic anemias These crises can occur later in infancy due to increased demands on the bone marrow, leading to a drop in reticulocyte levels.
The main reason behind gamma irradiation of the blood products is to prevent
Rationale:
Gamma irradiation of blood products is primarily utilized to prevent graft-versus-host disease (GVHD). This process inactivates donor lymphocytes that could attack the recipient’s tissues, ensuring patient safety during transfusions.
A: transfusion-related bacterial infections. Bacterial growth is typically managed through sterilization and proper storage methods, rather than gamma irradiation, which targets cellular components rather than bacterial agents.
B: transfusion-related viral infections. Viruses are usually addressed through screening and viral inactivation techniques, making gamma irradiation unnecessary for preventing viral transmission in blood products.
D: allergic reactions. Allergic reactions stem from immune responses to proteins or other components in blood products, not from GVHD, which involves lymphocyte activity rather than allergens.
A 45-year-old man presents with deep vein thrombosis of the right femoral vein. Three months ago, he received a diagnosis of systemic lupus erythematosus (SLE). In addition to confirming SLE, laboratory testing also documented the presence of a lupus anticoagulant (LAC). There is no family history of venous thrombosis. Current medications include hydroxychloroquine. Laboratory testing shows normal results for a complete blood cell count and for tests of liver and kidney function. Special coagulation testing confirms the persistence of an LAC. What is the most reasonable duration of warfarin anticoagulation for this patient?
Rationale:
Long-term anticoagulation is advised for this patient due to the presence of lupus anticoagulant, which significantly raises the risk of recurrent venous thromboembolism in systemic lupus erythematosus. Continuous management is essential to prevent complications.
A: 3 months This duration is insufficient given the persistent lupus anticoagulant and the established link between SLE and recurrent thrombotic events, necessitating a longer treatment approach.
B: 1 year While this duration may seem reasonable, current guidelines suggest that patients with lupus anticoagulant require indefinite anticoagulation due to heightened thromboembolic risk, warranting more extended therapy.
C: 6 months Similar to 3 months, this time frame fails to address the ongoing risk associated with lupus anticoagulant in a patient with systemic lupus erythematosus, which calls for prolonged anticoagulation.
A 3.2-kg, 40-week's-gestational age male is born by spontaneous vaginal delivery to a 20-year-old white female. Past maternal medical problems reveal a history of easy bruising that required splenectomy at 18 years of age. Current coagulation studies of the mother include a prothrombin time of 12 seconds, a partial thromboplastin time of 25 seconds, fibrinogen of 300 mg/dL, and a platelet count of 175,000. At 3 hours of age, the infant is noted to have multiple petechiae and a platelet count of 15,000. The most likely diagnosis is
Rationale:
Maternal idiopathic thrombocytopenic purpura is the most likely diagnosis. The mother's history of easy bruising and splenectomy suggests an autoimmune disorder affecting her platelet count, which can lead to neonatal thrombocytopenia.
A: neonatal alloimmune thrombocytopenia involves maternal antibodies attacking fetal platelets, typically occurring in siblings of affected infants, which is not indicated in this case.
B: congenital von Willebrand disease features abnormal bleeding due to defective clotting factors, not solely low platelet counts, and does not align with the mother's history or the infant's condition.
D: congenital leukemia would present with more severe symptoms, including additional cytopenias and often abnormal blood cell morphology, which are not described in this scenario.
The criteria for successful bone marrow transplantation in thalassemic patients include all the following EXCEPT
Rationale:
Successful bone marrow transplantation in thalassemic patients does not require the absence of bone deformities. These deformities can be a consequence of the disease but do not preclude transplantation success.
A: age younger than 15-year-old Age under 15 is a crucial factor, as younger patients typically have better outcomes due to their overall health and the body's ability to recover.
B: no hepatomegaly Hepatomegaly signifies liver enlargement, which can complicate transplantation; thus, its absence is a necessary criterion for ensuring a smoother and safer transplant procedure.
D: no iron overload Excessive iron accumulation poses serious risks during transplantation, making it essential to manage this condition prior to the procedure for optimal patient outcomes.
Ten years later, the patient described in Questions 3 and 4 experiences recurrent hemarthroses that become refractory to standard doses of factor VIII. The most likely cause of this is
Rationale:
B: The development of factor VIII antibodies is the most likely cause of recurrent hemarthroses becoming refractory to standard doses of factor VIII, indicating an immune response against the treatment.
A: Worsening hemophilia suggests a deterioration of the patient's condition, but without evidence of factor VIII antibodies, it wouldn't explain the refractory nature of the hemarthroses.
C: Development of AIDS might complicate the patient's health, yet it does not specifically relate to the refractory hemarthroses or directly impact factor VIII efficacy.
D: Development of hepatitis can affect overall health, but it does not typically cause the immune response that leads to the production of antibodies against factor VIII.
Of the following, the LEAST likely feature of Bernard-Soulier syndrome is
Rationale:
The feature least likely associated with Bernard-Soulier syndrome is severe thrombocytopenia.
Bernard-Soulier syndrome typically presents with moderate to mild thrombocytopenia rather than severe. This condition is characterized by large platelets and a defective glycoprotein complex, which leads to a bleeding tendency but not to the extent of severe platelet deficiency seen in other disorders.
A: autosomal recessive inheritance This genetic transmission pattern is associated with Bernard-Soulier syndrome, making it a characteristic feature of the disorder rather than an unlikely one.
C: giant Platelets The presence of giant platelets is a hallmark of Bernard-Soulier syndrome, directly resulting from the dysfunctional megakaryocytes producing abnormally large platelets.
D: abnormal ristocetin test The abnormal ristocetin test is indicative of impaired platelet function in Bernard-Soulier syndrome, confirming the presence of glycoprotein defects rather than being an unlikely feature.
The best diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH) is
Rationale:
Flow cytometry provides the most accurate detection of PNH by identifying abnormal red blood cell populations with specific surface markers. This method allows for precise quantification and characterization of affected cells, making it the gold standard for diagnosis.
A: acidified serum hemolysis (HAM) test This test assesses red blood cell susceptibility to hemolysis but lacks the specificity and sensitivity needed for reliable PNH diagnosis compared to flow cytometry.
B: sucrose lysis test While this test can indicate hemolysis, it does not differentiate between various hemolytic anemias and lacks the detailed cellular analysis provided by flow cytometry.
C: complement assay This assay evaluates complement activation but does not directly assess the unique cell surface markers associated with PNH, limiting its diagnostic utility in this context.